NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis → He cracked the code to crypto… (From Weiss Ratings) (Ad) Free RVPH Stock Alerts $1.71 -0.12 (-6.30%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.60▼$1.8150-Day Range$1.70▼$3.9052-Week Range$1.60▼$8.30Volume406,738 shsAverage Volume310,487 shsMarket Capitalization$47.74 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Reviva Pharmaceuticals alerts: Email Address Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside855.2% Upside$16.33 Price TargetShort InterestBearish4.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector519th out of 928 stocksPharmaceutical Preparations Industry239th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.48% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 1.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 3.7 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Reviva Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows9 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to remain at ($0.93) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 8.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Reviva Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesMay 15 at 8:12 AM | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15 at 8:00 AM | globenewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 14 at 3:13 PM | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14 at 8:00 AM | globenewswire.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13 at 8:00 AM | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 10, 2024 | prnewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 9, 2024 | globenewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 4, 2024 | morningstar.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 25, 2024 | finance.yahoo.comRVPH: Full Year 2023 ResultsApril 25, 2024 | businesswire.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 15, 2024 | msn.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | globenewswire.comReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.comReviva Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 27, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual MeetingMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic PromiseMarch 14, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 putSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today5/15/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+795.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,409.55% Return on Assets-291.73% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book9.13Miscellaneous Outstanding Shares27,920,000Free Float19,032,000Market Cap$50.95 million OptionableOptionable Beta0.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 59)Founder, CEO, President & Director Comp: $560kMr. Narayan Prabhu (Age 52)Chief Financial Officer Comp: $412.5kKey CompetitorsBioLineRxNASDAQ:BLRXBolt BiotherapeuticsNASDAQ:BOLTRockwell MedicalNASDAQ:RMTICleneNASDAQ:CLNNReneo PharmaceuticalsNASDAQ:RPHMView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 26,854 shares on 5/10/2024Ownership: 3.588%Citadel Advisors LLCSold 62,600 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1-year target prices for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 855.2% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2024? Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of the year. Since then, RVPH stock has decreased by 66.8% and is now trading at $1.71. View the best growth stocks for 2024 here. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) issued its quarterly earnings results on Monday, April, 15th. The company reported ($0.35) EPS for the quarter. Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.59%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
